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Abstract
Objective: Selective estrogen receptor modulators (SERMs) 
such as tamoxifen play a role in increasing the risk of 
developing uterine Fibroid.
Methods: Case report.
Case: Mrs. 47 years old, Para 6, presented with chief 
complaints of vaginal bleeding since a year ago. The patient 
was diagnosed with breast carcinoma 4 years ago and has 
had a right mastectomy followed by 6 cycles of chemotherapy 
which is  then continued with tamoxifen treatment for 4 
years, USG examination revealed uterine myoma to which we 
performed bilateral salphingoophorectomy hysterectomy, 
with anatomic pathology results of a uterine Fibroid and 
chronic endometritis.
Conclusions: Selective estrogen receptor modulators 
(SERMs) such as tamoxifen exhibit antagonistic reactions 
in breast tissue which makes it appropriate to be used in 
the treatment of breast cancer. However, they can also be 
potentially agonistic on estrogen receptors in the uterus, 
which can cause the growth of uterine Fibroid. Nevertheless, 
the benefi ts of adjuvant tamoxifen for breast cancer 
outweighs its potential for developing uterine Fibroid and 
endometrial carcinoma, because metastatic breast cancer 
will always be fatal, whereas uterine myoma and endometrial 
cancer caused by the effects of tamoxifen can be prevented 
by regular evaluation and total hysterectomy.
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Abstrak
Tujuan: Selektif estrogen reseptor modulator (SERMs) 
seperti tamoksifen berperan dalam meningkatkan risiko 
mengembangkan mioma uteri.
Metode: Laporan Kasus.
Kasus: Ny 47 tahun Para 6, datang dengan keluhan 
perdarahan dari jalan lahir yang dirasakan ibu selama 1 
tahun ini, pasien telah menderita kanker payudara 4 tahun 
yang lalu dan telah dilakukan mastektomi mammae dextra 
dilanjutkan kemoterapi 6 siklus kemudian dilanjutkan dengan 
pengobatan tamoksifen selama 4 tahun ini, dari pemeriksaan 
USG didapatkan adanya mioma uteri kemudian dilanjutkan 
dengan tindakan histerektomi salphingooforektomi 
bilateral, dengan hasil patologi anatomi suatu mioma uteri 
dan endometritis kronis.
Kesimpulan: Selektif estrogen reseptor modulator (SERMs) 
seperti tamoksifen merupakan reaksi antagonis reseptor es-
trogen pada jaringan payudara yang digunakan dalam pen-
gobatan kanker payudara, tetapi dapat berpotensi agonis 
pada reseptor estrogen pada uterus sehingga dapat me-
nyebabkan pertumbuhan mioma uteri. Tetapi penggunaan 
tamoksifen  ajuvan untuk kanker payudara lebih bermanfaat 
dibandingkan dengan potensinya untuk mengembangkan 
mioma uteri dan karsinoma endometrium, karena  kanker 
payudara metastatik akan selalu berakibat fatal, sedangkan 
mioma uteri dan kanker endometrium yang ditimbulkan 
oleh efek tamoksifen dapat dicegah dengan evaluasi teratur 
dan dilakukan tindakan total histerektom.
Kata kunci: kanker payudara, mioma uteri, tamoksifen.
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INTRODUCTION
Uterine fi broid occurs in 20-25% of women 
of reproductive age.1 According to a study 
conducted in the United States, the incidence of 
uterine Fibroid cases occurring in Caucasians is 
8.9 / 1000 wheras the incidence of people of color 
is 30.9 / 1000. The prevalence of uterine Fibroid 
increases with age, peaking in women in their 
40s. A study found that 77% of cases requiring 
hysterectomy revealed uterine Fibroids.2
Breast cancer accounts for 30% of all cancers 
in women and causes about 20% of all cancer 
deaths, second only to lung cancer. Since the 
beginning of its incident in the 1980s, cases of 
breast cancer has increased 3% per year in the 
western world, and it is estimated that cancer will 
overtake cardiovascular disease as the leading 
cause of death in the early twenty-fi rst century. 
Tamoxifen is the endocrine treatment of choice 
for selected patients with all stages of breast 
cancer.3 Tamoxifen has been known to reduce 
the incidence of contralateral cancer by 40%.4
It is estimated that 2 out of 1000 women 
/ year develop endometrial carcinoma while 
receiving tamoxifen therapy, compared with 1 
in 1000 women reported by SEER in the general 
population. For breast cancer patients who 
already have a high risk for endometrial cancer, 
the added risk of long-term tamoxifen therapy is 
miniscule compared to its known benefi ts.5
The factors causing uterine Fibroid are 
unknown, but there are 2 theories.  Stimulation 
theory argues that estrogen is an etiological 
factor, this is further supported by the following 
facts : Uterine Fibroid grows faster during 
pregnancy,this neoplasm has never ovured before 
menarche, uterine Fibroid usually atrophies after 
menopause, endometrial hyperplasia is found 
with uterine myoma.  Cellnest Theory states that 
the occurrence of uterine Fibroids depends on 
immature muscle cells contained in the Nest cell 
which can then be stimulated continuously by 
estrogen.6,7
Selective Estrogen Receptor Modulators 
(SERMs) such as tamoxifen are nonsteroidal 
hormones that act as antiestrogens in breast 
tissue.8 They were fi rst approved by the US Food 
and Drug Administration for the treatment of 
breast cancer in 1978 and until now, tamoxifen is 
used among women of all ages for the treatment 
of all stages of breast cancer. Tamoxifen reduces 
the risk of subsequent contralateral breast cancer 
and also its recurrence and risk of mortality. 
Upon further investigation, it was discovered that 
tamoxifen is associated with the development of 
endometrial cancer. Tamoxifen has a complex 
mechanism of action including anti-estrogenic 
activity in the breast and estrogenic effect on 
other tissues, including endometrium.9
Tamoxifen is a fi rst generation breast 
cancer drug, developed in the 1970s, and is 
currently designed for the treatment of breast 
cancer. Tamoxifen acts as an estrogen receptor 
antagonist in breast tissue, but in bone and 
uterine tissue Tamoxifen acts as an estrogen 
receptor agonist, so as to maintain bone mineral 
density in postmenopausal women. Therefore 
tamoxifen is also considered for the treatment of 
osteoporosis.10 Tamoxifen can act as an agonist 
for uterine endometrial hyperplasia and polyp 
production, thus possibly increasing the risk of 
endometrial cancer.3
Tamoxifen has a complex mechanism of action 
including anti-estrogenic activity in the breast and 
estrogenic effects on other tissues, including the 
endometrium.9 Women taking tamoxifen must be 
informed of the risk of endometrial proliferation, 
endometrial hyperplasia, endometrial cancer, and 
uterine sarcoma, and any effects caused during 
tamoxifen therapy such as abnormal vaginal 
bleeding, vaginal discharge. An encounter with 
any of the mentioned symptoms warrant an 
immediate full examination. Postmenopausal 
women taking tamoxifen should be monitored for 
symptoms of endometrial hyperplasia or cancer, 
premenopausal women treated with tamoxifen 
who are not at risk for uterine cancer do not 
need additional monitoring outside of routine 
gynecological care, unless the patient has been 
identifi ed as having a high risk of endometrial 
cancer. Routine endometrial surveillance has 
not been proven effective in increasing early 
detection of endometrial cancer in women using 
tamoxifen and is not recommended. If atypical 
endometrial hyperplasia develops, appropriate 
gynecological management must be performed, 
and the use of tamoxifen must be reassessed.11
Before conducting tamoxifen therapy, 
initial gynecologic screening should be done, 
these include transvaginal ultrasonography, 
sonohysterography and hysteroscopy to assess 
endometrial conditions. The level of endometrial 
cancer risk in women treated with tamoxifen 
depends on dose and time. Studies show that at 
an early stage, the degree of histology and biology 
of tumors that develop in individuals treated 
with tamoxifen 20 mg / day are no different from 
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those that appear in the general population. 
Some reports have indicated that women who 
are treated with tamoxifen doses higher than 40 
mg / day are more likely to develop tumors that 
are more biologically aggressive.
Women who take tamoxifen must be 
informed of the potential for endometrial 
proliferation, endometrial hyperplasia, dometrial 
cancer, and uterine sarcoma, they must be 
educated to immediately report abnormal 
symptoms such as vaginal bleeding, spotting, 
or leukorrhea. The ability of tamoxifen to 
induce endometrial malignancy and other 
histopathological conditions seems to differ 
between premenopausal and postmenopausal 
women.
Women with endometrial lesions such as 
polyps diagnosed before tamoxifen treatment 
have a higher risk of developing atypical 
endometrial lesions. Therefore, these patients 
require annual gynecological examinations such 
tranvaginal ultrasound and even hysteroscopy. 
These examinations must be carried out even 
when patients present without symptoms. 
Hysterectomy can be considered in women with 
atypical endometrial hyperplasia. Tamoxifen can 
be used again after hysterectomy in endometrial 
carcinoma, this requires a consult with a doctor 
who has experience treating breast cancer.
CASE
A 47-year-old female, Para 6, presented with 
chief complaints of vaginal since a year ago, 
bleeding was found in the form of spotting and 
the patient has been menopausal since 4 years 
ago. The patient was diagnosed with breast 
carcinoma 4 years ago and right mastectomy 
has been performed, followed by 6 cycles of 
chemotherapy which is then continued with 
tamoxifen treatment for 4 years. Results of a 
physical examination revealed a BMI of 31.25 
(class 1 obesity). Our patient also suffered 
from hypertension since undergoing tamoxifen 
therapy with a dose of 20 mg twice a day and 
routinely consumes 10 mg of amlodipin to treat 
this hypertension. Gynecological examination 
found normal inspection of urethra and vulva, In 
examinations with speculum, portio was slippery, 
external uterine ostium was closed, fl uor albus 
was negative, fl uxus was positive. Upon bimanual 
examination, we found a slippery portio, closed 
uterine externum, uterine cavities enlarged as big 
as a swan’s egg, closed uterine ostium, negative 
fl uor albus and positive fl ux. 
There was no mass felt in both adnexas and 
parametrium was limp. Laboratory examination 
results reveal Hb: 13.4 gr / d, Ca 125: 16.28 U / mL, 
CEA: 1.64 U / mL, GDS: 148 gr / dl. From ultrasound 
examination, we found an enlarged uterus with 
size 13x12x11 cm, and a hyperechoic mass 5x4x3 
cm in size was seen in the  myometrium with a 
clear boundary. In the Doppler picture was an 
appearance of feeding arteries which is suggestive 
of uterine myoma. We then proceeded with 
bilateral salphingoophorectomy hysterectomy 
then the results of PA revealed a uterine Fibroid 
and chronic endometritis.
Figure 1. Uterine Fibroid in a patient receiving Tamoxifen
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DISCUSSION
In this patient, the uterine fi broid she suffered 
has caused symptoms, namely bleeding and 
pain. This complaint has disturbed the patient’s 
quality of life and interferes with her daily activity 
due to constant menstruation and pain that does 
not go away with analgesics. Thus, operative 
management is indicated in this patient.
Considering that this patient no longer has a 
need for her reproductive function, is undergoing 
tamoxifen therapy for breast cancer for four 
years and that tamoxifen increases the risk of 
endometrial malignancy as much as 1.3 to 7.5, we 
have decided to perform Salphingoophorectomy 
hysterectomy on this patient. Another factor 
which made us favour this decision is that 
salphingooforectomi aims to increase the effi cacy 
of tamoxifen therapy against breast cancer.
Patients are given an explanation that 
surgical removal of the uterus and ovaries will 
be performed to remove uterine myoma and to 
prevent endometrial cancer that can be caused 
by tamoxifen therapy and to also increase the 
effi cacy of tamoxifen therapy against breast 
cancer.
Salphingoophorectomy hysterectomy can 
solve the patient's problem and reduce the side 
effects caused by tamoxifen therapy on the risk 
of endometrial cancer.
Tamoxifen is an effective treatment in reducing 
the recurrence rate and mortality for breast cancer 
patients, on the other hand, the undesirable side 
effects of this treatment are an increased risk of 
endometrial cancer and changes to the genitals. 
The benefi ts of tamoxifen treatment for breast 
cancer outweigh the toxicity it causes, because 
metastatic breast cancer is always fatal, whereas 
the effects of endometrial cancer and changes in 
gynecological components can still be evaluated 
periodically and treated more quickly.
CONCLUSION
Uterine fi broid can occur due to estrogen 
stimulation caused by the use of tamoxifen 
which is an estrogen receptor agonist in uterine 
and endometrial tissue. Nevertheless, Tamoxifen 
treatment is urgently needed in these patients to 
prevent contralateral metastases. For this patient, 
it was decided to perform HTSOB to remove 
uterine myomas and to prevent endometrial 
cancer and to also increase the effectiveness of 
tamoxifen therapy.
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